Since the future of the Bio-similar medicine seems to be bright one in cancer treatment, a sub-project of Pars Health City, execution of a bio-similar medicine production plant can increase the cancer recovery rate as. 

Anin CO. is involved in this project as the designer and general contractor.

The subject of this project is the construction of a MAB medicine production plant based on EUGMP standard. The preliminary area of the plant is estimated to be around 7000 m2 in two floors. The plant will produce four types of biosimilar medicine with a total annual capacity of 450,000 doses.